JANUARY 30-31, 2015
The Wyndham New Yorker Hotel
481 Eighth Avenue, New York, New York 10001
NYSAM, 11 North Pearl Street, Suite 801, Albany, New York 12207
Phone (518) 689-0142 Fax (518) 426-1046 nysam@asapnys.org
Continuing Medical Education
This Live activity, NYSAM’s 11th Annual Statewide Conference “Intersection of Science, Treatment
and Policy”, with a beginning date of 1/30/2015, has been reviewed and is acceptable for up to
14.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim
only the credit commensurate with the extent of their participation in this activity.
AMA/AAFP Equivalency:
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category
1 credit(s)™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed
credit earned must be reported as Prescribed, not as Category 1.
ABAM Equivalency:
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled
in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 12.35 AMA PRA Category 1 Credit(s)™ for completing NYSAM’s 11th Annual Statewide Conference “Intersection of Science, Treatment and Policy”.
Conference Sponsors:
The New York Community Trust, Edith and Jules Klein Fund
BioDelivery Sciences International
Hazelden Betty Ford Foundation
Lakeview Health
Mallinckrodt Pharmaceuticals
Marworth Treatment Center
McLean Hospital
Mountainside Treatment Center
Newport Academy
Roxane Laboratories, Inc.
Sierra Tucson
Silver Hill Hospital
SMART Management, Inc.
Sovereign Health Group
TrueTox Laboratories, LLC
“Marijuana: Problems and Opportunities in New York State”
This conference, which has been designed for physicians, medical students, residents, and fellows, features stateof-the-art presentations highlighting the most recent developments in addiction medicine.
Friday, January 30, 2015
8:00 am - 8:15 am
Welcome and Introductions
8:15 am - 9:00 am
Effects of Marijuana on Adolescents
Timothy Brennan, MD, MPH, Addiction Institute of New York
This presentation will review the currently published scientific literature regarding the effects of
marijuana on adolescents. It will highlight the facts (and only the facts), regarding what we
currently know about marijuana and adolescents.
9:00 am - 9:45 am
Approaches to Treatment for Marijuana Use Disorders in Youth
Marc Fishman, MD, John Hopkins
Adolescents are particularly vulnerable to the problematic effects of marijuana use, including the
development of marijuana use disorders (MUDs) in the addiction spectrum. There is
considerable evidence for the effectiveness of several treatment approaches for MUDs in youth,
as well as other promising approaches with emerging support. Given current societal
ambivalence about the risks of marijuana use and the associated decrease in perceived harm
among youth and their families, enhancement of motivation and treatment engagement are the
most important targets for improving effectiveness.
9:45 am - 10:15 am
Adolescent Addiction Treatment in New York
Greg Bunt, MD, Daytop Village, President of NYSAM
Steven Hanson, NYS OASAS
William A. Fusco, Executive Director, Dynamic Youth Community, Inc.
Carol Ann Slattery, EdD, LCSW-R, Assistant Vice President, Outpatient Services, Samaritan Village
Adolescent addiction is an important focus in NY. This presentation will describe the current
state as well a planned changes in the delivery of addiction services to youth. Medicaid Redesign, Program opportunities, level of care determination, care coordination and use of evidence
based practices will be included in the discussion. Particular attention will be paid to marijuana
use and treatment.
10:15 am - 10:30 am
10:30 am - 11:15 am
Legal Ramifications of Marijuana Arrests for Juveniles
Sandeep Kandhari, JD, NYC Legal Aid Society
Sandeep Kandhari is an Assistant Attorney-in-Charge with the Legal Aid Society’s
Juvenile Rights Practice. Mr. Kandhari will share insight from his experiences representing
juveniles both in the adult and juvenile system. The presentation will include a description of
how marijuana cases proceed in the justice system and the consequences of prosecuting
juveniles for marijuana possession.
11:15 am - 12:00 pm
Discouraging Marijuana Consumption by Young People: Lessons from Tobacco Control
Allyn Taylor, JD, JSD, Affiliate Professor of Law, University of Washington School of Law
As an increasing number of states decriminalize or legalize marijuana, strategies must be developed to prevent promotion of and discourage consumption by young people. This presentation
will consider lessons that can be learned from widely used tobacco regulatory strategies, including prohibitions and restrictions on tobacco advertising, promotion and sales to young people.
Friday, January 30, 2015
12:00 pm - 1:15 pm
1:15 pm - 2:00 pm
Lunch—Non CME Topic Tables
Medical Marijuana: What Do We Know?
Brian F. Sands, MD, Assistant Clinical Professor, Department of Psychiatry, New York University
School of Medicine
Marijuana has been cultivated and used by human beings for at least a millennium. Consideration of it’s legitimate uses as a therapeutic agent have been complicated by the social and, therefore, legal perspective of recreational marijuana use. Although a large segment of the US population use this drug recreationally, use is a crime (except recently in some states) and research has
been constrained. There are a number of potential indications for marijuana and a less restrictive
research environment could help us understand it’s role as a pharmaceutical agent. Because of
the social and legal context, leaders in several states have passed legislation, which has put marijuana in a unique position among pharmaceuticals.
2:00 pm - 2:45 pm
Finding the Medicine in Marijuana: New Developments in Cannabinoid
Stephen Schultz, Vice President, Investor Relations, GW Pharmaceuticals
For centuries, many cultures and societies have utilized the cannabis plant for
therapeutic purposes. However, the development of cannabinoid and
cannabis-derived medications has not kept pace with that of other modern
prescription products, such as opioids. Only in the last two decades have scientists uncovered
the mechanism of action by which cannabinoids affect the human brain and body. It is well
known that tetrahydrocannabinol (THC) is psychoactive and can produce unacceptable CNS
side effects. However, different formulations of cannabinoids and different delivery systems
may affect the risk/benefit profile of cannabinoid and cannabis-derived products. Recent clinical
research has produced intriguing results, and further study is underway to elucidate more fully
the analgesic and other therapeutic potential of these medications.
2:45 pm - 3:00 pm
3:00 pm - 4:00 pm
Implementation of the Compassionate Care Act in New York State
Sandi Toll, Assistant Counsel to the Governor
New York State will soon be enhancing healthcare for person suffering from a number of serious
health conditions when we implement Compassionate Care Act. To guide that implementation,
draft regulations have been developed and will be finalized with considerable input from diverse
stakeholders. This plenary will provide an update on New York State’s readiness for implementation of the Compassionate Care Act and an overview of the work that remains.
4:00 pm - 4:30 pm
Video on Tobacco and Marijuana Promotion
4:30 pm - 5:00 pm
Prevention and Primary Care Approaches
Norman Wetterau, MD
Drug and alcohol use and abuse are a contagious pediatric problem. We need to address this
early as we do other diseases rather than wait until there is full-blown addiction. There are evidence based methods of prevention. There are screening instruments that primary care practices
can use and early interventions but these are time consuming. With the development of integrated health care systems evidence based prevention and early interventions could be incorporated
into primary care practices. ASAM members should be leaders in these affords.
5:15 pm - 6:30 pm
6:30 pm
Annual NYSAM Meeting
Networking Reception
This conference, which has been designed for physicians, medical students, residents, and fellows,
features state-of-the-art presentations highlighting the most recent developments in addiction medicine.
Saturday, January 31, 2015
7:00 am - 7:45 am
Continental Breakfast and Registration
7:45 am - 8:00 am
Welcome and Opening Remarks
Gregory Bunt, MD, Daytop Village, NYSAM President
Edwin Salsitz, MD, FASAM, Mount Sinai Beth Israel
8:00 am - 8:45 am
Heroin Addiction: Genetics, Epigenetics and Novel Treatment
Yasmin Hurd, PhD, Mount Sinai
Sponsored By:
8:45 am - 9:30 am
Sponsored By:
9:30 am - 10:15 am
The talk will provide insights about the molecular consequences of heroin addiction by direct
studies of the human brain. Information provided will emphasize the relevance of genetics to
molecular alterations in human heroin abusers including epigenetic disturbances induced by
the repeated use of heroin throughout their lives. The talk will also introduce the involvement
of the cannabinoid system to heroin abuse vulnerability and to the development of a cannabinoid, cannabidiol, as a novel treatment for heroin craving.
Implementing Naltrexone as a Part of a Comprehensive Program to Treat Opioid-Dependent
Adam Bisaga, MD, Professor of Psychiatry at CUMC, Director, Nicotine Laboratory, NYS
Psychiatric Institute
Buprenorphine have been mainstay of office-based treatment for opioid dependence.
However, it is not universally effective, nor it is acceptable to all patients. A significant
proportion of opioid dependent patients, will fail to stabilize on buprenorphine, continuing to
use opioids or dropping out of treatment. For others, the prospect of long-term maintenance
on an opioid medication is not attractive. An alternative is to offer treatment with the opioid
receptor antagonist naltrexone, which acts by a different mechanism and as such has the
potential to become an effective treatment option for patients who have failed prior agonist
trials or those who are not suitable or agreeable to agonist maintenance. Naltrexone is fitting
for individuals seeking an opioid-free approach to recovery as it offers the promise of securing
abstinence and circumventing the high relapse rates currently observed following opioid
detoxification or agonist maintenance discontinuation. This workshop will help clinicians
adopt naltrexone in the addiction medicine practice setting. Covered topics include: the evolution of antagonist-based treatment of opioid dependence, selection of candidates, clinical
strategies to initiate treatment in active users, and addressing safety concerns and clinical problems emerging during long-term maintenance treatment with naltrexone. Finally, we will discuss how to best integrate naltrexone alongside buprenorphine in a comprehensive officebased program to treat opioid-dependent individuals.
Why Shouldn’t We Test Health Care Workers for Drugs
Arthur L. Caplan, PhD, Drs. William F and Virginia Connolly Mitty Chair, Director,
Division of Medical Ethics, NYU Langone Medical Center
I will be discussing issues around the ethics of drug testing physicians and other healthcare
workers, including the accuracy of testing and the importance of protecting public health. The
need for early intervention to control addiction and how a high rate of abuse has an impact
on malpractice and mistakes will also be discussed.
10:30 am - 10:45 am
Coffee Break
10:45 am - 11:15 pm
Considerations in the Drug Testing of Physicians
Jeffrey Selzer, MD
This presentation will critically review the effectiveness of workplace drug testing in general
and drug testing in safety sensitive work such as providing health care in particular. Possible
licensing and disciplinary consequences will also be discussed.
11:15 am - 12:15 pm
Keynote Address: Electronic Cigarettes
Maciej L. Goniewicz, PharmD, PhD, Department of Health Behavior, Division of Cancer
Prevention and Population Studies, Roswell Park Cancer Institute
Electronic nicotine delivery systems, commonly called e-cigarettes, are contributing to a
growing percentage of nicotine use. Limited research is available on the use of e-cigarettes.
E-cigarettes create some issues: are they effective as a harm-reduction tool to assist in quitting
or will we see an increase in nicotine use because the devices are not strongly associated with
the smoker stereotype. This presentation will provide an overview of the e-cigarette devices
and how they are used as well as review current research in the field which examines their use
as a harm reduction tool and as a gateway to the use of nicotine products.
12:15 pm - 1:30 pm
Lunch—Poster Session
NYSAM Updates: Gregory Bunt, MD, Daytop Village, NYSAM President
THC Recap: Norman Wetterau, MD
1:30 pm - 2:15 pm
Buprenorphine Use in Combined Chronic Pain and Opioid Addiction
Sandra D. Comer, PhD, Professor of Clinical Neurobiology in the Department of Psychiatry at
the College of Physicians and Surgeons of Columbia University, and a Research Scientist at the
New York State Psychiatric Institute
In recent years, the incidence of prescription opioid abuse has skyrocketed in the U.S. Part of
the problem stemmed from improper prescribing of high-potency opioids to patients with
chronic pain. However, some patients with chronic pain received proper prescriptions and
still developed opioid use disorder. This lecture will present data from laboratory studies that
were designed to shed light on the relationship between pain and opioid abuse. In addition, a
clinical trial was conducted to examine the utility of sublingual buprenorphine for treating the
co-occurring disorders.
2:15 pm - 3:15 pm
Behavioral Health Updates from the New York City Department of Health and Mental
Hygiene: Primary Care and Behavioral Health Initiatives, Correctional Health and Substance
Use Programming, and Medicaid and Behavioral Health Implications for NYC
Hillary Kunins, MD, MPH, Assistant Commissioner for the Bureau of Alcohol and Drug Use at
the Department of Health and Mental Hygiene (DOHMH)
Gary S Belkin, Executive Deputy Commissioner for the Division of Mental Hygiene at the New
York City Department of Health and Mental Hygiene
Jessica Kattan, MD, MPH, Director of the Primary Care Integration Unit at New York City
Department of Health and Mental Hygiene’s Bureau of Alcohol and Drug Use, Prevention,
Care, and Treatment
Ross MacDonald, MD, Medical Director of the Bureau of Correctional Health Services for The
NYC Department of Health and Hygiene
In this panel presentation, key representatives from the New York City Department of Health
and Mental Hygiene will provide updates on key initiatives and activities from the City Health
Department, including our work in advancing primary care-behavioral health integration
around alcohol and opioid use, integrating substance use-related programming and treatment
in the NYC jail system, and the opportunities and challenges for the transition in Medicaid and
Behavioral Health.
3:15 pm - 3:30 pm
3:30 pm - 4:15 pm
Coffee Break
Harm Reduction 2015
Sharon Stancliff, MD, Medical Director, Harm Reduction Coalition
This session will provide an update on the evidence for harm reduction interventions and on
related New York State policies. Information will be provided on syringe access programs
and on developments in the availability of naloxone. Lower threshold approaches to prescribing buprenorphine will be discussed.
4:15 pm - 5:00 pm
Case Studies—Ultrapotent Synthetic Cannabinoids and “Fake LSD” - The Evolution of The
Designer Drug Market
Timothy J. Wiegand, MD, FACMT, FAACT, Director of Medical Toxicology and Toxicology
Consult Service, Associate Clinical Professor of Emergency Medicine, URMC and Strong Memorial Hospital
Paul M. Wax, MD, FACMT, Executive Director, American College of Medical Toxicology
Nicholas Nacca, MD, Medical Toxicology, SUNY Upstate Poison Center and SUNY Upstate
Medical Toxicology Fellowship Program
This presentation will provide an overview of the changing landscape of synthetic and designer
drug use in New York State since Federal and state laws were enacted which successfully restricted use of these chemicals in 2012. New York State Poison Center data, information obtained from Emergency Department visits, Medical Toxicology consult service census’ and epidemiologic data presented by the CDC will be described in order for the audience to have an
appreciation of the changing chemicals, availability and patterns of use related to these drugs
that has occurred over the past few years. In addition to an overview of the newer designer
drug use, including recent outbreaks of toxicity, new and novel chemicals will be discussed
including NBOME compounds, or ultra-potent designer amphetamines, which have been misrepresented as LSD or sold as “synthetic or ‘fake’ LSD”. The presenters will also describe patterns of intoxication and key differences in the pharmacology of NBOME compounds compared to other substituted amphetamines. Designer stimulants, next-generation ultra-potent
synthetic cannabinoids and other classes of drugs including designer benzodiazepines will be
included in this presentation. The lecture will end with a clinical case discussion including audience participation via a Question and Answer format which will allow for illustration of the
newer synthetic and designer drug-related intoxications as well as methods of testing for these
chemicals and treating patients intoxicated by the newer synthetic and designer drugs.
5:00 pm
Wrap-Up, Final Announcements. CME Certificate Distribution
Edwin Salsitz, MD, FASAM, Mount Sinai Beth Israel
Chris Dufault
District Manager
New England/New York
300 E. Lombard St. Suite 1610
Baltimore, Maryland 21202
1 (774) 345-0569
Ameritox helped pioneer the prescription drug monitoring necessary to address
the national epidemic of prescription drug misuse, abuse, and diversion. As the
nation’s trusted leader in Pain Medication Monitoring SolutionsSM, Ameritox
provides medical and business professionals with data-driven analysis and tailored solutions that can improve patient care and prevent tragedy. Ameritox,
headquartered in Baltimore, Md., has 800 employees nationwide and laboratory facilities in Greensboro, N.C.
BioDelivery Sciences International
Steven J. Patterson
Regional Sales Director
801 Corporate Center Drive, Suite 210
Raleigh, NC 27607
BioDelivery Sciences International is a specialty pharmaceutical company focusing on pain and addiction medicine. We utilize our novel and proprietary BioErodible Muco-Adhesive (BEMA) and other drug delivery technologies to develop and commercialize new applications of proven therapies aimed at addressing
important unmet medical needs. We focus on the development and commercialization of products related to pain management and addiction medicine. We
believe our drug delivery technologies and products are best applied to address
these critical unmet medical needs.
We look forward to working with you to enhance patient care.
Hazelden Betty Ford Foundation
Lisa Frankel
Outreach Manager
322 8th Avenue, 12th Floor
New York, New York 10001
(917) 975-8666
The Hazelden Betty Ford Foundation is a force of healing and hope for individuals, families and communities affected by addiction to alcohol and other
drugs. It is the nation’s largest nonprofit treatment provider. With 15 sites, the
Foundation offers prevention and recovery solutions nationwide and across the
entire continuum of care to help youth and adults reclaim their lives from the
disease of addiction. It includes the largest recovery publishing house in the
country, a fully accredited graduate school of addiction studies, an addiction
research center, an education arm for medical professionals and a unique children’s program, and is the nation’s leader in advocacy and policy for treatment
and recovery.
Lakeview Health
Jackie Cream
1900 Corporate Square Boulevard
Jacksonville, FL 32216
(904) 899-4535
Lakeview Health is a nationally recognized residential addiction treatment program in Jacksonville, FL. We believe complete health, wellness and life balance
are a possible for everyone; that people can change to become life-saving and
not life draining, and by fostering a path that leads toward “Finding Your True
North” the greatest rewards are achieved. Our “Servant Leadership” culture empowers staff to act as a tool for families and individuals struggling with chaos
and pain. We offer an addiction treatment program that is safe and built on a
holistic approach that addresses the medical, psychological, spiritual and physical
needs of our patients. For information, contact (866) 460-8416 or visit us at
Marworth Treatment Center
Liz Walker
Lily Lake Road
Waverly, PA 18471
(800) 442-7722
Marworth Treatment Center, a division of the Geisinger Healthcare System, provides alcoholism and chemical dependency treatment services across the continuum of care. At Marworth, a foundation of treatment is established for continuing recovery that includes individual, group, family and recreational therapy. All
clients are discharged with a full continuing care plan, which enables them to
continue with the supports they will need to live healthy lives. In addition to
treating the general adult population, Marworth provides specialized services for
Healthcare Professionals and Uniformed Professionals. Marworth understands
the complicated circumstances that present unique challenges to the treatment
process regarding these populations. We work closely with referral sources, licensing boards, family members, co-workers, etc., to provide the best possible
treatment plan and professional re-entry. Marworth is licensed by the Pennsylvania Department of Health and JCAHO accredited since 1982. Nestled in the
beautiful mountains of Northeast Pennsylvania, recovery is confidential and
compassionate. For more information about Marworth’s services, please call 1(800) 442-7722 or visit www.marworth.org
Mallinckrodt Pharmaceuticals
Ed Ryan
675 McDonnell Boulevard
Hazelwood, MO 63042
(860) 488-0657
Mallinckrodt Pharmaceuticals is a global specialty pharmaceutical business that
develops, manufactures, markets and distributes specialty pharmaceutical products
and medical imaging agents. We provide customers with a broad portfolio of specialty generics to treat pain, ADHD, opiate and alcohol addiction, depression and
insomnia. For more information, visit www.mallinckrodt.com.
McLean Hospital
Rocco Iannucci, M.D.
Director, McLean Fernside
Box 1070, 162 Mountain Road
Princeton, MA 01541
(978) 464-2141
The Alcohol and Drug Treatment Programs at Harvard Medical School-affiliated
McLean Hospital offers a full continuum of care: inpatient detox, residential, partial, and outpatient services. We offer both short- and long-term residential care;
buprenorphine treatment in adult programs; clinical expertise in treating cooccurring psychiatric disorders; and individualized treatment plans. New to the
McLean alcohol and drug treatment continuum, McLean Borden Cottage offers
exceptional treatment in an unsurpassed setting. For more information about the
program or admission, please call (800) 906-9531 or email
Mountainside Treatment Center
Jennifer Marciano, M.S.
Route 7, Box 717
Canaan, CT 06018
(860) 689-3351 or (646)354-4249
Mountainside, a leader in alcohol and drug addiction treatment, is now a destination for a comprehensive continuum of care. We offer a range of programs including Detox, Primary Residential, Extended Care and Outpatient. Under our
Integrative Care Model of treatment we are able to sequentially guide clients
through each stage of recovery or offer assistance at various independent stages.
In all our programs, clients receive individualized treatment plans designed to provide thorough and restorative healing to meet their unique needs. Our multidisciplinary team of professionals collaborates with clients, families and healthcare
partners every step of the way, resulting in high engagement, motivation and positive outcomes for our clients.
Newport Academy
Carter Barnhart
64 Double Hill Road
Bethlehem, CT 06751
(610) 213-4191
At Newport Academy, our goal is sustainable healing. We strongly believe that
the self-destructive behavior in which teens are participating are external manifestations, or symptoms, of underlying, internal issues. Through healing the underlying issues that are causing teens to act out—trauma, abandonment, low selfesteem, anxiety, depression, abuse, neglect, and incongruent family systems—we
achieve the most positive, long-term results. The maladaptive coping mechanisms
for which we see teens enter treatment include self-harm, substance abuse, eating
disorders, conduct disorders, and other forms of self-destructive behavior. The
Newport Academy Program provides the safety, support and, above all, the unconditional love that teens and their families need in order to heal. By incorporating multiple modalities of psychological and experiential therapies, and a dedication to treating the entire family, we offer the highest quality teen treatment program.
Lee Marks
150 Headquarters Plaza
East Tower, 5th Floor
Morristown, NJ 07960
(973) 936-6908
Orexo is a specialty pharma company with commercial operations in the United
States and R&D in Sweden developing improved treatments using proprietary
drug delivery technology and commercial operations in the United States. The
company is commercializing its proprietary product, ZUBSOLV® sublingual tablets, for maintenance treatment of opioid dependence, in the United States. The
ZUBSOLV® sublingual tablet is a novel formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual technologies. Orexo has a
portfolio of two approved and revenue generating products currently marketed
under license in the EU and US. Orexo AB, with its headquarters in Sweden, is
listed on NASDAQ OMX Stockholm Exchange and its American Depositary Receipts (ADRs) trade on the OTCQX marketplace in the U.S. under the symbol,
“ORXOY”. The largest shareholders are Novo A/S and HealthCap. For information about Orexo, please visit http://www.orexo.com/us/.
Roxane Laboratories, Inc.
Debbie Kutner
National Account Manager
P.O. Box 16532
Columbus, OH 43216
(973) 627-4521
Roxane Laboratories, Inc. is a recognized leader for the research, development,
sales, and marketing of multisource pharmaceutical products. Located in Columbus, Ohio, Roxane operates out of a modern 500,000-square-foot manufacturing and laboratory facility that spans more than 70 acres and currently employs more than 1,200 people. To help support the unique Addiction Therapy
community of clinics and patients, we feature several products in our portfolio,
as well as a team of dedicated service professionals. For more information on
the products and services made available by Roxane, please visit our website at
Sierra Tucson
Jane Davis
97 Wright Road
Rockville Centre, NY 11570
(516) 316-7657
Compassionate Healing Through An Integrative Approach - Sierra Tucson’s
unique approach to treating behavioral health issues and complex mental health
disorders combines the best of neuroscience and integrative therapies to support
each person’s capacity for resiliency, healing and recovery. Sierra Tucson’s staff­
honor and are sensitive to each patient’s individual cultural needs. Services provided for addiction/co-occurring disorders, trauma/PTSD, mood & anxiety, complex pain, eating recovery, connections and continuing care.
Silver Hill Hospital
Heather Porter
208 Valley Road
New Canaan, CT 06840
(800) 899-4455
Founded in 1931, Silver Hill Hospital is an independent, not-for-profit psychiatric hospital. Silver Hill provides treatment for adolescents and adults with psychiatric and substance use disorders. Silver Hill is distinct in offering a full continuum of care with both inpatient treatment as well as longer-stay residential
Transitional Living Programs. Our specialty programs include Addiction, Chronic
Pain and Recovery, Co-Occurring Disorders and Dialectical Behavior Therapy.
Silver Hill Hospital is an academic affiliate of the Yale University School of Medicine, Department of Psychiatry.
SMART Management, Inc.
Michael Carruthers
Director Sales & Implementations
66 Pavilion Avenue
Providence, RI 02905
SMART Software is a comprehensive paperless electronic health record. SMART
Software provides automated solutions to address the critical business functions
of Insurance Billing, Admissions, Clinical and Medical Service Delivery, Incident
Report Management and the Quality Control reports needed to effectively
manage your treatment facility. Whether you operate medication-assisted treatment, outpatient, mental health, residential or a combination of services SMART Software is all you will need. We know that centralizing and sharing
data is critical with today's demands for efficiency. SMART's EHR sets the stage
for managing multiple locations and/or modalities within one software application.
Sovereign Health Group
Iris Maclean, MS
Regional Outreach Manager
1211 Puerta Del Sol
San Clemente, CA 92673
Cell: (949) 441-6545
Admissions: (866) 850-9581
TrueTox Laboratories, LLC
Linda Stio BSN, RN, BC, CARN
Clinical Marketing Manager
50 Rose Place
Garden City Park, NY 11040
(516) 734-0417
Sovereign Health Group offers treatment for Addiction, Dual Diagnosis, and
Mental Health. Our treatment team utilizes a foundation of evidence-based
treatment modalities, support systems, and blend experiential therapies to create
finely balanced treatment programs. At Sovereign Health Group, we have 24/7
Admissions specialists standing by to complete a free confidential telephone assessment and verification of insurance benefits. Chat Live at www.sovcal.com/
Truetox’s Medication Monitoring programs have been designed to make urine
drug monitoring as easy and efficient as possible for physicians, patients and
payers. Truetox is owned and operated on Long Island, licensed by New York
State, CLIA Certified, who has a superior clinical team that can address patient
testing and also provide pathways to recovery when necessary. Our team consists of a Lab Director boarded by the American Board of Forensic Toxicology,
Masters level Lab Scientists certified by New York State, a Physician certified by
the American Board of Addiction Medicine as well as SAMSHA, a board certified Pain Management and Addictions Registered Nurse and account executives
who all work with physicians and staff to integrate urine drug monitoring into
their continuum of medication or addictions management.
Gary Belkin
Gary S Belkin is currently the Executive Deputy Commissioner for the Division of Mental Hygiene at the New York City
Department of Health and Mental Hygiene. He was previously Medical Director Behavioral Health in the Health and Hospitals Corporation of the City of New York, which operates the New York City 11 public hospitals, and was formerly Chief
of Psychiatry (Interim) at Bellevue Hospital. He brings extensive experience in day-to-day clinical operations and policy
development in urban health delivery systems, as well as in developing and studying emerging approaches to public mental
health and served as Associate Professor and Director, Program in Global Mental Health, New York University School of
Medicine. He was founding Director of the NYU Program which was developed to advance innovative implementation
and policy approaches to scale and improve population mental health strategies, as well as efforts to extend the impact of
behavioral health sciences on other social sectors and outcomes. These efforts ranged from adapting mental health skills to
the work of street-level gun violence interrupters in New York City, to designing task-shift based solutions to scaled integrated care for common mental disorders in rural Haiti. As common mental disorders grow in their contribution to overall
disease burden, the challenge of delivery systems and public health policy is not only to innovatively expand access, but to
do that in ways that accent complex, community, participatory, and early/preventive strategies that act on the connections
between mental health morbidity and multiple social and health outcomes.
Adam Bisaga, MD
Dr. Adam Bisaga is a Professor of Psychiatry at the Columbia University Medical Center, and a Research Scientist at the
New York State Psychiatric Institute.
Dr. Bisaga received his medical degree from Jagiellonian University Medical College in Krakow, Poland and he trained in
psychiatry and behavioral pharmacology of addictions at the Institute of Psychiatry and Neurology in Warsaw, Poland. He
completed his psychiatric residency at the North Shore University Hospital in Manhasset, NY and in 1997 began working at
the Division of Substance Abuse at Columbia University, first as a research fellow and later as a research psychiatrist. Here
he received training in addiction psychiatry research under the mentorship of Drs. Marian Fischman and Herbert Kleber. He
was a recipient of a Career Development Award and a Principal Investigator on several R01 grants funded by the National
Institute of Dug Abuse. His current research interests include: 1) development of animal and human laboratory models of
addictions, 2) testing new medications for opioid, cocaine, alcohol and tobacco use disorders, and 3) dissemination of evidence-based treatments into community programs.
Besides his research contributions Dr. Bisaga’s has been actively involved in teaching, both locally and well as nationally. He
has served on several UN expert panels to develop substance abuse treatment guidelines and conducted training for practitioners internationally. In addition to the research and teaching work at the University, Dr. Bisaga also maintains a private
practice in general and addiction psychiatry.
Timothy Brennan, MD, MPH
Timothy Brennan, MD, MPH is an Attending Physician and Director of the Fellowship in Addiction Medicine at The Addiction Institute of New York at Roosevelt Mount Sinai Hospital in New York City. He completed his fellowship in Addiction Medicine at The Addiction Institute, a fellowship in Medical Ethics at Harvard Medical School, and a residency in Pediatrics at New York Presbyterian Hospital / Weill Cornell. He also completed an intern year in Internal Medicine at
Georgetown University Hospital. Dr. Brennan has spoken at state, national and international levels about addiction issues,
particularly as related to young adults. He is the co-editor of the forthcoming Essentials of Addiction Medicine and was
recently appointment by Governor Cuomo to serve on a the New York State Justice Center’s Medical Review Board. He
received his B.S. in Foreign Service from Georgetown, and his combined M.D./M.P.H from Tulane University School of
Medicine and School of Public Health and Tropical Medicine.
Gregory Bunt, MD
Dr. Gregory Bunt graduated from NYU School of Medicine in 1983, completed his residency in Psychiatry at the AECOM in
1987, and a Fellowship in Addiction Psychiatry at NYU (1989), and is currently as an Assistant Clinical Professor of Psychiatry at NYU. He is a diplomat of the American Board of Psychiatry and Neurology in Addiction Psychiatry. Dr. Bunt is currently the medical director of Daytop Village and Daytop International. He was a Past-President of the American Society
of Adolescent Psychiatry. Dr. Bunt now serves as the President of the New York Society of Addiction Medicine and the
President of the International Society of Addiction Medicine.
Arthur L. Caplan, PhD
Currently the Drs. William F and Virginia Connolly Mitty Professor and founding head of the Division of Bioethics at New
York University Langone Medical Center in New York City.
He is the co-founder and Dean of Research of the NYU Sports and Society Program and the head of the ethics program in
the Global Institute for Public Health at NYU.
Prior to coming to NYU he was the Sidney D. Caplan Professor of Bioethics at the University of Pennsylvania Perelman
School of Medicine in Philadelphia where he created the Center for Bioethics and the Department of Medical Ethics.
Caplan has also taught at the University of Minnesota, where he founded the Center for Biomedical Ethics, the University of
Pittsburgh, and Columbia University. He received his PhD from Columbia University. (Caplan is the author or editor of
thirty-two books and over 600 papers in peer reviewed journals. His most recent books are Contemporary Debates in Bioethics (Wiley 2013) and Ethics in Mental Healthcare: A Reader (MIT Press, 2013).
He has served on a number of national and international committees including as the Chair, National Cancer Institute Biobanking Ethics Working Group; the Chair of the Advisory Committee to the United Nations on Human Cloning; the Chair
of the Advisory Committee to the Department of Health and Human Services on Blood Safety and Availability; a member
of the Presidential Advisory Committee on Gulf War Illnesses; the special advisory committee to the International Olympic
Committee on genetics and gene therapy; the ethics committee of the American Society of Gene Therapy; the special advisory panel to the National Institutes of Mental Health on human experimentation on vulnerable subjects and the Wellcome
Trust on research in humanitarian crises. He served as the Co-Director of the Joint Council of Europe/United Nations Study
on Trafficking in Organs and Body Parts. He is currently the ethics advisor to DOD/DARPA on synthetic biology, a member of the National Council on Youth Sports Safety and a member of the Ethics and Ebola Working Group of the World
Health Organization.
Caplan writes a column on bioethics for NBC.com. He is a commentator on bioethics and health care issues for WebMD/
Medscape. He is a regular commentator on medicine and science for WGBH radio in Boston. He appears frequently as a
guest and commentator on various other national and international media outlets.
Caplan is the recipient of many awards and honors including the McGovern Medal of the American Medical Writers Association and the Franklin Award from the City of Philadelphia. He received the Patricia Price Browne Prize in Biomedical Ethics for 2011. He was a person of the Year-2001 from USA Today. He was described as one of the ten most influential people in science by Discover magazine in 2008. He has also been honored as one of the fifty most influential people in American health care by Modern Health Care magazine, one of the ten most influential people in America in biotechnology by
the National Journal, one of the ten most influential people in the ethics of biotechnology by the editors of Nature Biotechnology. In 2014 he was selected to receive the Public Service Award from the National Science Foundation/National Science Board which honors individuals and groups that have made substantial contributions to increasing public understanding of science and engineering in the United States.
He holds seven honorary degrees from colleges and medical schools. He is a fellow of the Hastings Center, the NY Academy of Medicine, the College of Physicians of Philadelphia, the American College of Legal Medicine and the American Association for the Advancement of Science.
Sandra D. Comer, PhD
Dr. Sandra Comer is a Professor of Clinical Neurobiology in the Department of Psychiatry at the College of Physicians and
Surgeons of Columbia University, and a Research Scientist at the New York State Psychiatric Institute. Dr. Comer received
her undergraduate degree at Vanderbilt University (9187), and completed her graduate training at the University of Michigan, where she received her Master of Science (1988) and Doctorate in Philosophy (1992) degrees for her research on the
effects of opioid drugs in the laboratory of Dr. James H. Woods. Following graduate school, Dr. Comer completed a two
year post-doctoral fellowship at the University of Minnesota, Minneapolis. There she received training in preclinical animal
models of cocaine self-administration in rodents and non-human primates in the laboratory of Dr. Marilyn Carroll. In 1993,
Dr. Comer began working at the Division of Substance Abuse at Columbia University. Here she received training in human
preclinical studies under the mentorship of Dr. Marian Fischman and Dr. Richard Foltin. Dr. Comer’s research focus has
been on the development and testing of novel approaches to the treatment of opioid dependence, and the influence of sex
differences and hormonal fluctuations on responses to pain and opioid medications. Email: sdc10@columbia.edu
Marc Fishman, MD
Marc Fishman MD is an addiction psychiatrist and a member of the faculty of the Department of Psychiatry and Behavioral
Sciences at the Johns Hopkins University School of Medicine. He is the medical director of Maryland Treatment Centers, a
regional behavioral healthcare provider, which offers programs for residential and outpatient treatment of drug-involved
and dual-diagnosis adolescents and adults. He is a national expert on adolescent addiction treatment and program development. His academic work has focused on models of care and treatment outcomes for addictions in youth. He is a past
President of the Maryland Society of Addiction Medicine.
William A. Fusco
Mr. Fusco is a founder and Executive Director of Dynamic Youth Community, Inc. With over 40 years spent in the field of
substance abuse treatment, Mr. Fusco specializes in substance abuse counseling services to adolescents, young adults and
their families. He remains an advocate to those in need of treatment by serving on various government and professional
coalitions, panels and committees. Mr. Fusco is immediate past chairman of the Coalition for Community Services. He is a
board member of Therapeutic Communities Association of New York and is a Board Member of the NYS Association of
Substance Abuse Providers. Mr. Fusco became interested in the field of substance abuse treatment after himself completing
Phoenix House.
Maciej L. Goniewicz, PharmD, PhD
Dr. Maciej L. Goniewicz is an Assistant Professor of Oncology at the Department of Health Behavior, Roswell Park Cancer
Institute in Buffalo, NY. He earned a Pharm.D. degree (2002) and a Ph.D. in Toxicology and Pharmacology (2007) from
the Medical University of Silesia, Poland. He completed his postdoctoral fellowships in Clinical Pharmacology and Tobacco
Control at the University of California San Francisco and in Smoking Cessation Treatment in Queen Mary University of
London, UK. Dr. Goniewicz’s primary research area is in nicotine pharmacology, with a focus on nicotine dependence and
smoking cessation. He has research experience in smoking cessation behavioral treatment, pharmacotherapy, and pharmacokinetics in both clinical and community-based settings. Dr. Goniewicz’s current research is focused on new nicotinecontaining products and alternative forms of tobacco. He examines safety and efficacy of electronic nicotine delivery devices, commonly called e-cigarettes. These studies include the laboratory evaluation of the products, pharmacological and toxicological assessment, surveys among their users, and their potential application in harm reduction and smoking cessation.
Steve Hanson
Steve Hanson is the Associate Commissioner of Treatment for the New York State Office of Alcoholism and Substance
Abuse Services. He is responsible for the oversight of state operated treatment programs, adolescent services, criminal justice and Recovery services. Steve has over 30 years of experience in the field as a treatment provider, educator and consultant.
Yasmin Hurd, PhD
Dr. Yasmin Hurd is Professor of Psychiatry and Neuroscience at the Icahn School of Medicine in New York, USA. She is an
internationally renowned neuroscientist whose translational research examines the neurobiology of drug abuse and related
psychiatric disorders. She is highly published in the field and leads a team of investigators in molecular biology, behavioral
neuropharmacology, genetics and neuroimaging to study the human brain as well as translational animal models. Dr. Hurd
is also Director for the Center for Addictive Disorders within the Mount Sinai Behavioral Health System which covers one
of the largest addiction populations in the US providing clinical care supported by science-based medicine and advanced
state-of-the-art research.
Sandeep Kandhari, JD
Sandeep Kandhari is an Assistant Attorney-in-Charge for the Legal Aid Society’s Juvenile Rights Practice. Mr. Kandhari supervises a multi-disciplinary practice that handles juvenile delinquency cases. Mr. Kandhari graduated from New York University School of Law in 2006 and has worked for the Legal Aid Society since graduating. He has represented children in
child welfare and delinquency cases and adults in the criminal cases.
Jessica Kattan, MD, MPH
Jessica Kattan, MD, MPH, is the Director of the Primary Care Integration Unit at New York City Department of Health and
Mental Hygiene’s Bureau of Alcohol and Drug Use, Prevention, Care, and Treatment. Dr. Kattan trained in primary care/
internal medicine at Brigham and Women’s Hospital in Boston, MA, and in medical epidemiology with CDC’s Epidemic Intelligence Service. She has a broad background in public health, including experience in infectious diseases, chronic diseases,
and substance use. Her current work focuses on promoting safe opioid prescribing, increasing access to buprenorphine treatment for opioid dependence, and supporting adoption of universal screening for alcohol use.
Hillary Kunins, MD, MPH
Dr. Hillary Kunins is the Assistant Commissioner for the Bureau of Alcohol and Drug Use at the Department of Health and
Mental Hygiene (DOHMH) and a general internist with certification in addiction medicine. Since 2012, when Dr. Kunins
joined the Department as Assistant Commissioner, she has led the Department’s efforts to promote public health approaches
to reducing the health and social consequences of drug and alcohol use in NYC, including prescription opioid misuse, best
practices in integrating substance use in primary systems, prevention of overdose and surveillance and reporting on drug and
alcohol use. Before joining the Department, she worked in the Bronx for 16 years providing primary and addiction-related
care to patients in both community health centers and in substance abuse treatment programs. Dr. Kunins also served as
Medical Director of the Hub 2 Methadone Maintenance Program, in the Division of Substance Abuse at Einstein and Director of the Primary Care/Social Internal Medicine Residency Program at Montefiore Medical Center/Albert Einstein College of
Medicine. Dr. Kunins completed her MD and MPH at Columbia University and her internal medicine training at Montefiore
Medical Center’s Primary Care Program.
Ross MacDonald
Ross MacDonald is Medical Director of the Bureau of Correctional Health Services for The NYC Department of Health and
Hygiene. Dr. MacDonald earned a BS in Biology and English from Cornell University in Ithaca, NY and an MD from Weill
Medical College of Cornell University in New York City. He completed a residency in Social Internal Medicine at Montefiore Medical Center in the Bronx, NY. Dr. MacDonald’s interest in the incarcerated as a vulnerable population dates back
to his time teaching English literature in a maximum security prison in upstate New York. He helped found the Montefiore
Transitions clinic for the recently incarcerated, and prior to working for the Department of Health maintained a patient panel enriched in formerly incarcerated patients. Dr. MacDonald’s role as Medical Director involves oversight of care provided
in the NYC jail system, formulation and application of DOHMH policy on a wide range of medical conditions, training of
clinical staff, oversight of Quality Improvement efforts, pursuit of compassionate release, ongoing review of adverse events
as well as direct patient care. He is the recipient of a 2013 Department of Health Distinguished Service Award and Co-author
of the 2014 American Journal of Public Health Paper of the Year, "Solitary Confinement and Risk of Self-Harm Among Jail
Nicholas E. Nacca, MD
Nicholas Nacca is an Board Certified Emergency Physician who is currently completing his second year of fellowship in Medical Toxicology at SUNY Upstate Medical University and the Upstate Poison Center in Syracuse, NY. He completed
his undergraduate training at University of Rochester in Neuroscience, and earned his medical degree and residency certification at SUNY Upstate in Syracuse.
Sharon Stancliff, MD, Medical Director
Sharon Stancliff, MD, FAAFP is the Medical Director of the Harm Reduction Coalition, a national training and advocacy organization; she is based in New York City.
Dr. Stancliff is currently funded by the AIDS Institute, New York State Department of Health and the New York City Department of Health and Mental Hygiene to provide overdose prevention services with naloxone, both directly through education and capacity building. She also provides consultation on drug treatment, harm reduction and overdose prevention nationally and maintains a small buprenorphine practice. International experience has included consulting on drug user health
with the World Health organization and work in Ukraine and in Zanzibar with various international agencies.
Dr. Stancliff graduated from the School of Medicine at University of California at Davis, did her Family Practice residency a t
the University of Arizona and completed the AIDS Institute-sponsored Nicolas Rango HIV Clinical Scholars Program at Beth
Israel Medical Center in New York City. She is board certified in Family Medicine, a Fellow of the American Academy of
Family Practice, and certified by the American Board of Addiction Medicine.
Stephen Schultz
Mr. Schultz has 25 years of experience in investor relations, financial communications and media relations. Most recently,
from January 2011 to March 2013, Mr. Schultz served as Senior Director of Investor Relations and Corporate
Communications at Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular health. Prior to Amarin, Mr. Schultz served
as the Executive Director of the Jackson Hole Center for the Arts, a not-for-profit organization aimed at promoting artistic
creativity and education. Mr. Schultz’s extensive investor relations and corporate communications experience also includes
senior-level roles at Acusphere, Shareholder.com (a Nasdaq company), Manufacturer’s Services Limited, Wang Global and
the ForeFront Group. Mr. Schultz holds a B.A. Degree from St. Lawrence University.
Brian F. Sands, MD
Dr. Sands is currently the Section Chief for SUD Services at VA NY Harbor Healthcare System, where he is a responsible for
chemical dependency services across the continuum of care. As a Clinical Assistant Professor in The NYU Department of Psychiatry, he supervises addiction psychiatry fellows at VA and provides teaching and supervision of medical students and psychiatry residents.
Dr. Sands was born in New York City and grew up on the North shore of Long Island. He attended the University of Albany
and the State University of New York, Upstate Medical School. After graduation from Upstate in 1983, he continued his
training in Boston as a resident in psychiatry at The Tufts New England Medical Center. Dr. Sands then remained at New
England Medical Center and completed a fellowship in clinical psychopharmacology and joined the faculty at Tufts Medical
School as an Assistant Professor. He was the Site Principal investigator of two studies addressing the efficacy of medication
treatment of cocaine dependence and participated in other research on pharmacological management of substance dependence.
After returning to the New York metropolitan area in 2000 to work at the North Brooklyn Health Network, Dr. Sands became involved in public health, partnering with Health and Hospitals Corporation and NYC Department of Health and
Mental Hygiene in expanding substance dependence services by facilitating office based buprenorphine treatment in Brooklyn. He led HHC in Tobacco Cessation Programs, starting at the North Brooklyn Health Network, was the Chairperson of
the Health & Hospitals Corporate Tobacco Cessation Task Force and was the Principle Investigator of a five-year New York
State Department of Health Grant to improve tobacco-related healthcare services throughout Brooklyn.
In addition to his work in Brooklyn, Dr. Sands contributed to the health of New Yorkers through work on the Substance
Dependence Subcommittee of the New York City Community Services Board and a three year appointment as Chairperson
of the Coalition for a Smoke Free New York City. Currently, he is a member of the Medical Advisory Panel of the New York
State Office of Alcoholism and Substance Abuse Services (OASAS).
Jeffrey Selzer, MD
Dr. Selzer is the Medical Director of Committee for Physician Health, New York State’s physician health program. He is also
the Director of North Shore-LIJ Health System’s Physician Resource Network, a confidential counseling program for the
health system’s practicing physicians and physician trainees. Prior to assuming these positions, he was Medical Director of the
Zucker Hillside Hospital and Director of Addiction Treatment Services for the North Shore-LIJ Health System, the thirdlargest, non-profit, secular healthcare system in the United States.
Dr. Selzer graduated from the University of Michigan Medical School and comleted a psychiatric residency at the University
of California, Los Angeles. He has been a Board Member of the New York Society of Addiction Medicine (NYSAM) for 10
years and has functioned in a number of roles for NYSAM (Secretary, Education Chair, and Member-at-Large). He also serves
as a Board Member and as the Research Committee Co-Chair for the Federation of State Physician Health Programs. He is a
member of the Editorial Board of the Journal of Substance Abuse Treatment and has also reviewed submission for the
Journal of Addiction Medicine.
Dr. Selzer is a Fellow of the American Society of Addiction Medicine and a Distinguished Fellow of the American Psychiatric
Association. He is an Associate Clinical Professor of Psychiatry at the Albert Einstein College of Medicine and at the Hofstra
North Shore-LIJ School of Medicine.
Carol Ann Slattery, EdD, LCSW-R
Dr. Carolann Slattery EdD, LCSW-R serves as the Assistant Vice President for Outpatient Services for Samaritan Village. Prior
to coming to Samaritan Village Dr. Slattery was the VP of Outpatient Services for Daytop Village. Dr. Slattery worked in
the educational field before entering into the not for profit industry. She served as a special education advocate and clini cal
specialist. She has worked with adolescents, adults along with their families for over twenty years within the judicial and
educational system. As a partner in the community she performs the role as an advocate for individuals with addiction and
mental health concerns. Dr. Slattery is an educational trainer for The Credentialed Alcoholism and Substance Abuse Counselor (CASAC) Program approved by the New York State Office of Alcoholism and Substance Abuse Services (OASAS) and an
adjunct professor. Dr. Slattery served as Vice President for the Special Education Coalition and has continued to be passionate in her work within the addiction field. Dr. Slattery has authored evidenced-based curriculums, literature reviews and
program evaluations.
Dr. Slattery earned her B.A. from Dominican College, attended LIU for her M.S. in Literacy and Education, a MSW from
New York University and Doctorate of Education and Psychology in Counseling Psychology, Administration and Supervision
from Argosy University.
Allyn Taylor, JD, JSD
Dr. Allyn Taylor is a leading expert in public health and international law. She is currently an Affiliate Professor of Law at
the University of Washington and has been a faculty member at Georgetown University Law Center, the University of Maryland Schools of Medicine and Law, and the Johns Hopkins Bloomberg School of Public Health. Previously, Dr. Taylor was a
senior health policy and legal adviser on the staff at the World Health Organization and was the senior legal adviser for the
negotiation of the Framework Convention on Tobacco Control (FCTC). She initiated the idea of the FCTC, the first treaty
negotiated at the World Health Organization, as part of her doctoral dissertation.
Professor Taylor has been an adviser to The World Bank, the World Health Organization, the Organization of American
States, the Pan American Health Organization, the Overseas Development Council, the Center for Science in the Public Interest, the Framework Convention Alliance, the National Campaign for Tobacco Free Kids, Realizing Rights: The Equitable
Globalization Initiative and the International Union Against Cancer. Internationally, she has lectured in programs in global
health law and diplomacy sponsored by Erasmus University, Rotterdam and the Graduate Institute in Geneva. She holds a
J.D. from the University of California at Berkeley and a doctorate in international law from Columbia University.
Paul M. Wax, MD, FACMT
Dr. Wax is the Executive Director of the American College of Medical Toxicology. Dr. Wax received his B.A from Dartmouth College, his M.D. from the Mount Sinai School of Medicine, his Emergency Medicine training at the UCLA Hospitals,
and his Medical Toxicology training at Bellevue Medicine Center / New York University. He is Board-certified in both Medical Toxicology and Emergency Medicine, and is a Fellow of the American College of Medical Toxicology.
Along with his part time role as the Executive Director of ACMT, Dr. Wax is a Clinical Professor in Surgery (Emergency Medicine) at the University of Texas, Southwestern School of Medicine where he is a member of the Section of Medical Toxicology and Director of the Medical Toxicology Clinic. Before joining ACMT in 2008 as its Executive Director, and the University of Texas Southwestern in 2006 as a part-time faculty member, Dr. Wax had faculty appointments in the Departments of
Emergency Medicine at the University of Rochester School of Medicine from 1991-2001 and the University of Arizona School
of Medicine from 2001-2006.
Dr. Wax previously served on the Board of Directors of ACMT from 1998-2008 serving as ACMT President from 20062008. During this tenure he chaired the ACMT Education Committee from 1998-2002. From 2002-2006 Dr. Wax served as
the National Director of ACMTs Consultation Network to support the ATSDR Regional Offices and was co-founder of ACMT’s Chemical Agent of Opportunity course. From 1997-2006 Dr. Wax also served as one of the American Board of Emergency Medicine’s appointee’s on the Medical Toxicology Subboard. During this time, Dr. Wax served as Editor of the Medical Toxicology Board Certification Examination as well as Chairman of the Subboard, and was the primary author of the
2004 Core Content of Medical Toxicology.
Dr Wax has also served as a consultant to the Centers for Disease Control NCEH’s Division of Laboratory Sciences and was a
member of NCEH/ATSDR Board of Scientific Counselors from 2006-2008.
Norman Wetterau, MD, FAAFP, FASAM
Dr. Wetterau has been a rural family physician for 40 years and helped start a group which now services 20,000 patients. He
currently does mainly addiction medicine in Danville and Nunda, NY. He is on the clinical faculty of Un of Rochester. He is
coauthor of the MSSNY Youth at Risk Report and previous chair of MSSNY addiction-mental health committee. He is past president of NYSAM, currently co chair of ASAMs chapter presidents’ council and on the ASAM board. He was awarded NYS Rural
Physician of the Year mainly for his work in rural Substance abuse.
Timothy J. Wiegand, MD, FACMT, FAACT
Timothy J. Wiegand, MD, FACMT, FAACT is Director of Toxicology at the University of Rochester in Rochester, New
York. He holds faculty appointment as an Associate Clinical Professor of Emergency Medicine at Strong Memorial Hospital
and Highland Hospital in Rochester, New York and is adjunct faculty and consultant toxicologist for the SUNY Upstate Poison
Center and SUNY Upstate Medical Toxicology Fellowship. In addition to these faculty positions Dr. Wiegand serves as Medical
Director for the Monroe County chemical dependence treatment program Huther Doyle and is a consultant detoxification and
acute opioid and alcohol withdrawal management specialist for the Syracuse Behavioral Health (SBH) Rochester, New York
detoxification facility site. Dr. Wiegand completed a combined fellowship at the University of California San Francisco in Medical Toxicology & Clinical Pharmacology. He has worked with several Poison Center throughout his tenure as Medical Toxicologist including as Director for the Ruth Lawrence Poison & Drug Information Center in Rochester, New York, before state
budget cuts forced the centers closure. Some of his areas of interest include cost-effective analysis of toxicology practice, billing
and reimbursement for toxicology consultation and treatment of drug and alcohol dependence. Dr. Wiegand won the American Society of Addiction Medicine (ASAM) 2013 (Chicago, IL) Medical Scientific Committee Award for the best abstract submission on Addictions Training during Medical Toxicology Fellowship and has been speaker on Pharmacology & Toxicology
content for the annual ASAM Review Course. In 2014 Dr. Wiegand joined the NYSAM Board as Communication Committee
Gregory C. Bunt, M.D.
Eric D. Collins, MD
Jun David, M.D.
Sharon Stancliff, M.D.
Norman Wetterau, M.D.
Immediate Past-President
Michael Delman, MD
Merrill Herman, M.D.
Jeffrey Selzer, MD
Regional Director to ASAM
Dorothy Lennon, M.D.
Membership Committee Chair
Edwin Salsitz, MD
Education and Program
Committee Chair
Brian Hurley, MD, MBA
Early Career Physician
Timothy Wiegand, MD
Communications Chair